---
name: Pilot Patient MS Age 39

data:
- 
  resourceType: Patient
  name: Mariela71 Simpson83
  gender: female
  birthDate: 1984-06-01
  extension:
  -
    url: http://hl7.org/fhir/us/core/StructureDefinition/us-core-birthsex
    valueCode: F

# CIN2 Pathology, Margins negative
-
  resourceType: DiagnosticReport
  code: LOINC#65753-6 Cervix Pathology biopsy report
  status: final
  conclusionCode:
  - SNOMEDCT#285838002 Cervical intraepithelial neoplasia grade 2 (disorder)
  effectiveDateTime: 2023-10-13

# Colposcopy Procedure
-
  resourceType: Procedure
  code: CPT#57455 Colposcopy of the cervix including upper/adjacent vagina; with biopsy(s) of the cervix
  performedDateTime: 2023-10-13
  status: completed

# CIN2 Pathology
-
  resourceType: DiagnosticReport
  code: LOINC#65753-6 Cervix Pathology biopsy report
  status: final
  conclusionCode:
  - SNOMEDCT#285838002 Cervical intraepithelial neoplasia grade 2 (disorder)
  effectiveDateTime: 2023-09-05

# Colposcopy Procedure
-
  resourceType: Procedure
  code: CPT#57455 Colposcopy of the cervix including upper/adjacent vagina; with biopsy(s) of the cervix
  performedDateTime: 2023-09-05
  status: completed


# LSIL Pap Smear and HRHPV+
- 
  resourceType: DiagnosticReport
  code: LOINC#21440-3 Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence] in Cervix by Probe
  status: final
  conclusionCode:
  - SNOMEDCT#720005005 Human papillomavirus deoxyribonucleic acid test positive, high risk on cervical specimen (finding)
  effectiveDateTime: 2023-07-13
- 
  resourceType: DiagnosticReport
  code: LOINC#47527-7 Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin prep
  status: amended
  conclusionCode:
  - SNOMEDCT#62051000119105 Low grade squamous intraepithelial lesion on cervical Papanicolaou smear (finding)
  effectiveDateTime: 2023-07-13



# LSIL Pap Smear and HRHPV+
- 
  resourceType: DiagnosticReport
  code: LOINC#21440-3 Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence] in Cervix by Probe
  status: final
  conclusionCode:
  - SNOMEDCT#720005005 Human papillomavirus deoxyribonucleic acid test positive, high risk on cervical specimen (finding)
  effectiveDateTime: 2022-07-28
- 
  resourceType: DiagnosticReport
  code: LOINC#47527-7 Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin prep
  status: amended
  conclusionCode:
  - SNOMEDCT#62051000119105 Low grade squamous intraepithelial lesion on cervical Papanicolaou smear (finding)
  effectiveDateTime: 2022-07-28

# NILM Pap Smear and HRHPV- Cotest
- 
  resourceType: DiagnosticReport
  code: LOINC#21440-3 Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence] in Cervix by Probe
  status: final
  conclusionCode:
  - SNOMEDCT#787724008 Human papillomavirus deoxyribonucleic acid test negative (finding)
  effectiveDateTime: 2017-10-26
- 
  resourceType: DiagnosticReport
  code: LOINC#47527-7 Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin prep
  status: amended
  conclusionCode:
  - SNOMEDCT#373887005 Negative for intraepithelial lesion or malignancy (finding)
  effectiveDateTime: 2017-10-26

# NILM Pap Smear
- 
  resourceType: DiagnosticReport
  code: LOINC#47527-7 Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin prep
  status: amended
  conclusionCode:
  - SNOMEDCT#373887005 Negative for intraepithelial lesion or malignancy (finding)
  effectiveDateTime: 2014-04-02


# Should be Treatment is recommended
results:
  HasRecentAbnormalScreening: true
  ManagementRecommendation: 
    short: 'Surveillance or Treatment'
    date: '2023-11-30'
    group: 'Managing Histology (I.2)'
    details:
    -  "Treatment of CIN2 is recommended unless the patient's concerns about the effect of treatment on future pregnancy outweigh concerns about cancer."
    -  "Excisional treatment is preferred, and treatment with ablation is acceptable."
    -  "Observation is unacceptable when the squamocolumnar junction or the upper limit of the lesion is not fully visualized or when the results of an endocervical sampling, if performed, is CIN 2+ or ungraded."
    -  "Observation includes colposcopy and primary hrHPV testing or cotesting at 6-month intervals for up to 2 years."